Mari et al. (25) demonstrated that SREBP2 overexpression was not found in obese patients and patients with other chronic liver diseases such as hepatitis C, but was rather a specific feature associated with NAFLD/NASH. Here, SREBF2 is linked to metabolic dysfunction-associated steatotic liver disease.